Abstract | BACKGROUND: PATIENTS AND METHODS:
Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma. RESULTS: The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non-hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months. CONCLUSIONS:
Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.
|
Authors | D G Savage, S A Rule, M Tighe, T J Garrett, M W Oster, R T Lee, J Ruiz, D Heitjan, M L Keohan, M Flamm, S A Johnson |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 11
Issue 5
Pg. 595-7
(May 2000)
ISSN: 0923-7534 [Print] England |
PMID | 10907954
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Deoxycytidine
- Gemcitabine
|
Topics |
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, pharmacology, therapeutic use)
- Deoxycytidine
(administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Hodgkin Disease
(drug therapy, pathology)
- Humans
- Infusions, Intravenous
- Lymphoma, Non-Hodgkin
(drug therapy, pathology)
- Male
- Middle Aged
- Recurrence
- Treatment Outcome
- Gemcitabine
|